Pharma: Clinic Roundup
Otsuka Pharmaceutical Co. Ltd., of Tokyo, said Phase IIb safety and efficacy data for delamanid, its investigational compound in multidrug-resistant tuberculosis (MDR-TB) were published in the New England Journal of Medicine. Results from the trial showed a 53 percent increase in sputum culture conversion (SCC) after two months for subjects who received delamanid 100 mg twice daily plus a background regimen (BR) consistent with World Health Organization treatment guidelines, compared with subjects receiving placebo plus BR alone.
Sign up for Perspectives FREE e-mail newsletter.
Outside the U.S.: 1-404-262-5423
Hours: Monday - Thursday, 8:30 am - 6:00 pm EST
Friday, 8:30am - 4:30 pm EST